Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “buy” rating reiterated by analysts at Jefferies Group LLC in a note issued to investors on Friday, July 14th. They presently have a $18.00 price target on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price target would suggest a potential upside of 6.89% from the company’s previous close.
Several other analysts have also weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $35.00 price objective (down previously from $45.00) on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 17th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $18.00 price objective (down previously from $21.00) on shares of Valeant Pharmaceuticals International in a report on Thursday, March 23rd. Deutsche Bank AG dropped their price objective on shares of Valeant Pharmaceuticals International from $19.00 to $18.00 and set a “hold” rating for the company in a report on Wednesday, April 19th. Piper Jaffray Companies reaffirmed an “outperform” rating and set a $10.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, April 14th. Finally, Scotiabank raised their price target on shares of Valeant Pharmaceuticals International from $12.00 to $14.00 and gave the company a “sector perform” rating in a report on Wednesday, May 10th. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and a consensus price target of $16.81.
Shares of Valeant Pharmaceuticals International (VRX) traded down 1.69% during trading on Friday, hitting $16.84. The stock had a trading volume of 12,242,293 shares. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.74. The stock’s 50-day moving average price is $15.93 and its 200 day moving average price is $13.36. The stock’s market cap is $5.86 billion.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $1.93. The company had revenue of $2.11 billion during the quarter, compared to analyst estimates of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The company’s revenue was down 11.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.08) earnings per share. On average, equities analysts forecast that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International’s (VRX) “Buy” Rating Reiterated at Jefferies Group LLC” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/07/28/jefferies-group-llc-reaffirms-buy-rating-for-valeant-pharmaceuticals-international-inc-vrx-updated.html.
In related news, Director Schutter Richard U. De bought 20,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Thursday, May 11th. The stock was acquired at an average price of $13.90 per share, with a total value of $278,000.00. Following the acquisition, the director now owns 70,572 shares of the company’s stock, valued at approximately $980,950.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.87% of the company’s stock.
Several hedge funds have recently made changes to their positions in VRX. Gruss & Co. Inc. acquired a new position in Valeant Pharmaceuticals International during the first quarter worth approximately $104,000. Financial Architects Inc increased its position in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the last quarter. Harbor Advisors LLC purchased a new position in Valeant Pharmaceuticals International during the first quarter worth about $110,000. WMS Partners LLC purchased a new position in Valeant Pharmaceuticals International during the first quarter worth about $116,000. Finally, Brave Asset Management Inc. purchased a new position in Valeant Pharmaceuticals International during the first quarter worth about $119,000. 50.42% of the stock is owned by institutional investors and hedge funds.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
